Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
14/YH/1056	147421	A multicenter, randomised, open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination of masitinib, gemcitabine and dexamethasone in patients with relapsed or refractory peripheral T-cell lymphoma	Number Agreed	2	2	Date Agreed	01/11/2017	3	13/03/2018	3	Recruitment Finished	
16/EM/0384	182787	An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention	Number Agreed	4	4	Date Agreed	31/01/2019	3	10/04/2018	3	Recruitment Finished	Worldwide recruitment numbers achieved
14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	50	50	Date Agreed	03/05/2018	51	01/05/2018	51	Recruitment Finished	
16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on	Range Agreed	6	8	Date Agreed	31/12/2018	23	12/11/2018	23	Recruitment Finished	Study wide Recruitment Target Met

		cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial										
17/LO/2114	238480	An observational study to evaluate the routine management, healthcare resource use and outcomes for patients with transfusion-dependent β-thalassaemia treated in the United Kingdom	Number Agreed	20	20	Date Agreed	30/11/2018	27	30/11/2018	27	Recruitment Finished	
15/SC/0295	177196	An open label, single arm, multicenter study to assess the clinical effectiveness and safety of Lynparza (olaparib) capsules maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy (ORZORA)	Range Agreed	2	4	Date Agreed	30/09/2018	5	06/07/2018	5	Withdrawn By Host	Oncology Research Service Moved to Another Hospital
17/LO/0438	217257	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT	Number Agreed	10	10	Date Agreed	30/06/2019	0	15/11/2018	0	Withdrawn By Host	Confirmation of C&C issued but sponsor did not issue green light and study was abandoned at site due to unforeseen resources issue at site